153 related articles for article (PubMed ID: 33829354)
1. FGFR leads to sustained activation of STAT3 to mediate resistance to EGFR-TKIs treatment.
Song X; Tang W; Peng H; Qi X; Li J
Invest New Drugs; 2021 Oct; 39(5):1201-1212. PubMed ID: 33829354
[TBL] [Abstract][Full Text] [Related]
2. Selumetinib overcomes gefitinib primary and acquired resistance by regulating MIG6/STAT3 in NSCLC.
Song X; Wang L; Tang W; Yuan L; Liu Q; Li J; Fan D
Arch Pharm Res; 2023 Dec; 46(11-12):924-938. PubMed ID: 38032449
[TBL] [Abstract][Full Text] [Related]
3. Cyclosporine A sensitizes human non-small cell lung cancer cells to gefitinib through inhibition of STAT3.
Shou J; You L; Yao J; Xie J; Jing J; Jing Z; Jiang L; Sui X; Pan H; Han W
Cancer Lett; 2016 Aug; 379(1):124-33. PubMed ID: 27264264
[TBL] [Abstract][Full Text] [Related]
4. Activation of IL-6R/JAK1/STAT3 signaling induces de novo resistance to irreversible EGFR inhibitors in non-small cell lung cancer with T790M resistance mutation.
Kim SM; Kwon OJ; Hong YK; Kim JH; Solca F; Ha SJ; Soo RA; Christensen JG; Lee JH; Cho BC
Mol Cancer Ther; 2012 Oct; 11(10):2254-64. PubMed ID: 22891040
[TBL] [Abstract][Full Text] [Related]
5. Reprogramming of TAMs via the STAT3/CD47-SIRPα axis promotes acquired resistance to EGFR-TKIs in lung cancer.
Lu J; Li J; Lin Z; Li H; Lou L; Ding W; Ouyang S; Wu Y; Wen Y; Chen X; Yue P; Wang Y; Liu P; Lu J; Zhang J; Feng W; Zhang X
Cancer Lett; 2023 Jun; 564():216205. PubMed ID: 37146936
[TBL] [Abstract][Full Text] [Related]
6. STAT3 inhibitor BBI608 enhances the antitumor effect of gefitinib on EGFR-mutated non-small cell lung cancer cells.
Wang Q; Lu B; Zhang Y; Yu J; Guo J; Zhou Q; Lv H; Sun Y
Hum Cell; 2021 Nov; 34(6):1855-1865. PubMed ID: 34370268
[TBL] [Abstract][Full Text] [Related]
7. Tyrosine kinase inhibitor-induced IL-6/STAT3 activation decreases sensitivity of EGFR-mutant non-small cell lung cancer to icotinib.
Wang J; Wang Y; Zheng C; Hou K; Zhang T; Qu X; Liu Y; Kang J; Hu X; Che X
Cell Biol Int; 2018 Sep; 42(10):1292-1299. PubMed ID: 29885023
[TBL] [Abstract][Full Text] [Related]
8. Lymecycline reverses acquired EGFR-TKI resistance in non-small-cell lung cancer by targeting GRB2.
Chen Y; Wu J; Yan H; Cheng Y; Wang Y; Yang Y; Deng M; Che X; Hou K; Qu X; Zou D; Liu Y; Zhang Y; Hu X
Pharmacol Res; 2020 Sep; 159():105007. PubMed ID: 32561477
[TBL] [Abstract][Full Text] [Related]
9. A novel STAT3 inhibitor W2014-S regresses human non-small cell lung cancer xenografts and sensitizes EGFR-TKI acquired resistance.
Zheng Q; Dong H; Mo J; Zhang Y; Huang J; Ouyang S; Shi S; Zhu K; Qu X; Hu W; Liu P; Wang Y; Zhang X
Theranostics; 2021; 11(2):824-840. PubMed ID: 33391507
[TBL] [Abstract][Full Text] [Related]
10. Fibroblast-secreted hepatocyte growth factor mediates epidermal growth factor receptor tyrosine kinase inhibitor resistance in triple-negative breast cancers through paracrine activation of Met.
Mueller KL; Madden JM; Zoratti GL; Kuperwasser C; List K; Boerner JL
Breast Cancer Res; 2012 Jul; 14(4):R104. PubMed ID: 22788954
[TBL] [Abstract][Full Text] [Related]
11. Synergistic effects of gefitinib and thalidomide treatment on EGFR-TKI-sensitive and -resistant NSCLC.
Xia X; Liu Y; Liao Y; Guo Z; Huang C; Zhang F; Jiang L; Wang X; Liu J; Huang H
Eur J Pharmacol; 2019 Aug; 856():172409. PubMed ID: 31132355
[TBL] [Abstract][Full Text] [Related]
12. EZH2 inhibitors reverse resistance to gefitinib in primary EGFR wild-type lung cancer cells.
Gong H; Li Y; Yuan Y; Li W; Zhang H; Zhang Z; Shi R; Liu M; Liu C; Chen C; Liu H; Chen J
BMC Cancer; 2020 Dec; 20(1):1189. PubMed ID: 33276757
[TBL] [Abstract][Full Text] [Related]
13. NF-κB activation is an early event of changes in gene regulation for acquiring drug resistance in human adenocarcinoma PC-9 cells.
Fukuoka M; Yoshioka K; Hohjoh H
PLoS One; 2018; 13(8):e0201796. PubMed ID: 30075033
[TBL] [Abstract][Full Text] [Related]
14. Gefitinib resistance resulted from STAT3-mediated Akt activation in lung cancer cells.
Wu K; Chang Q; Lu Y; Qiu P; Chen B; Thakur C; Sun J; Li L; Kowluru A; Chen F
Oncotarget; 2013 Dec; 4(12):2430-8. PubMed ID: 24280348
[TBL] [Abstract][Full Text] [Related]
15. Cigarette smoke induces aberrant EGF receptor activation that mediates lung cancer development and resistance to tyrosine kinase inhibitors.
Filosto S; Becker CR; Goldkorn T
Mol Cancer Ther; 2012 Apr; 11(4):795-804. PubMed ID: 22302097
[TBL] [Abstract][Full Text] [Related]
16. Targeting the epidermal growth factor receptor in non-small cell lung cancer cells: the effect of combining RNA interference with tyrosine kinase inhibitors or cetuximab.
Chen G; Kronenberger P; Teugels E; Umelo IA; De Grève J
BMC Med; 2012 Mar; 10():28. PubMed ID: 22436374
[TBL] [Abstract][Full Text] [Related]
17. Reciprocal regulation of miR-206 and IL-6/STAT3 pathway mediates IL6-induced gefitinib resistance in EGFR-mutant lung cancer cells.
Yang Y; Wang W; Chang H; Han Z; Yu X; Zhang T
J Cell Mol Med; 2019 Nov; 23(11):7331-7341. PubMed ID: 31507089
[TBL] [Abstract][Full Text] [Related]
18. TPCA-1 is a direct dual inhibitor of STAT3 and NF-κB and regresses mutant EGFR-associated human non-small cell lung cancers.
Nan J; Du Y; Chen X; Bai Q; Wang Y; Zhang X; Zhu N; Zhang J; Hou J; Wang Q; Yang J
Mol Cancer Ther; 2014 Mar; 13(3):617-29. PubMed ID: 24401319
[TBL] [Abstract][Full Text] [Related]
19. Continuous exposure of non-small cell lung cancer cells with wild-type EGFR to an inhibitor of EGFR tyrosine kinase induces chemoresistance by activating STAT3.
Tang J; Guo F; Du Y; Liu X; Qin Q; Liu X; Yin T; Jiang L; Wang Y
Int J Oncol; 2015 May; 46(5):2083-95. PubMed ID: 25695284
[TBL] [Abstract][Full Text] [Related]
20. mPRα mediates P4/Org OD02-0 to improve the sensitivity of lung adenocarcinoma to EGFR-TKIs via the EGFR-SRC-ERK1/2 pathway.
Lu X; Guan A; Chen X; Xiao J; Xie M; Yang B; He S; You S; Li W; Chen Q
Mol Carcinog; 2020 Feb; 59(2):179-192. PubMed ID: 31777985
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]